A clinical study of topical Rapamycin in Microcystic Lymphatic Malformations and Venous Malformations
Latest Information Update: 04 Dec 2025
At a glance
- Drugs Sirolimus (Primary)
- Indications Arteriovenous malformations; Lymphatic disorders; Vascular malformations
- Focus Adverse reactions
Most Recent Events
- 04 Dec 2025 New trial record
- 11 Nov 2025 According to a Quoin Pharmaceuticals media release, clinical testing in a number of indications including Microcystic Lymphatic Malformations and Venous Malformations, and other indications will start in 1H 2026.